News / Uncategorized
An early stage company is using CRISPR to treat cancer…
An early stage company is using CRISPR to treat cancer…
August 21, 2023
A very large private funding round just caught my eye. Caribou Biosciences, an early stage company developing CRISPR-based therapies for cancer, just raised $115 million in a Series C venture round. Caribou is a company I have been tracking for years. That’s largely because it was co founded by Jennifer Doudna. If we remember, Doudna was one of two scientists who won the Nobel Prize in Chemistry last October for her research on CRISPR technology. And what I love about Caribou is that it is taking on much more challenging problems than the early companies working on CRISPR-based therapies. The first-generation CRISPR companies have been focused on diseases caused by a single genetic mutation. They use CRISPR to simply correct that one mutation, thus curing the disease. It’s a simplification, but I think of these diseases as the “low-hanging fruit.”
�
That’s not meant to be a knock on their work. It’s very smart for the first CRISPR companies to tackle diseases that are well understood and caused by a single mutation. They are easier to fix. And the industry needs some early victories to generate even more excitement and investment into genetic editing companies. That said, CRISPR technology has advanced tremendously over the last three years. And it’s gotten to the point where Caribou is using it to develop CAR T therapies for cancer.
These therapies are much more complex, and nobody working in the CAR T space has really cracked the code yet. Early CAR T therapies demonstrated some limited efficacy without any major breakthroughs. So these are big undertakings. Caribou’s lead therapy targets non-Hodgkin’s lymphoma. It recently advanced into Phase 1 clinical trials. And the company’s second therapy, which is progressing toward preclinical trials, targets multiple myeloma. Caribou is developing these therapies for patients who have undergone traditional cancer treatments without much success.
The company’s goal is to cure cancer for these patients using next-generation CRISPR technology. It’s a great story and an exciting venture. What’s more, pharmaceutical giant AbbVie just engaged in a partnership with Caribou. Per the deal, AbbVie will pay Caribou $40 million upfront to use its CRISPR genetic editing and cell therapy technologies. And AbbVie has committed to paying up to $300 million in future milestone payments as the therapies it develops using Caribou’s technology progress.
This is very bullish for Caribou. And the big payday will help power Caribou’s lead therapy through the clinical trial process. So this is absolutely a company to watch. I wouldn’t be surprised to see Caribou go public within the next 12–18 months. Once it does, the company will make a fantastic investment target at the right valuation.
Share this article:
More in Uncategorized:
Ultra Clean Holdings (UCTT) July 25, 2024, Earnings Call Summary
Future Price Projections Participants: Rhonda Bennetto – Senior Vice President, Investor Relations Jim Scholhamer – Chief Executive Officer Sheri Savage...
An early stage company is using CRISPR to treat cancer…
July 26, 2024
APPLE, MICROSOFT, NVIDIA PRICE TARGET 🎯
Short term, price targets for the top three S&P 500 holdings
Short term, price targets for the top three S&P 500 holdings The following are my price targets for the very...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
July 25, 2024
Nvidia's Stake in Serve Robotics: A Game-Changer for AI-Powered Delivery?
The tech world was buzzing last week when news broke that AI chip giant Nvidia owns a 10% stake in Serve Robotics, a company specializing in autonomous sidewalk delivery robots. This revelation sent Serve's stock soaring an impressive 233% over two days. But what does this mean for the future of AI-powered delivery, and should investors jump on board?
The tech world was buzzing last week when news broke that AI chip giant Nvidia owns a 10% stake in...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
July 24, 2024
The Commercial Real Estate Crash
Its Ripple Effect on the Banking System and The Stock Market
The commercial real estate market is on the verge of a significant downturn, potentially mirroring the infamous 2008 financial crisis....
An early stage company is using CRISPR to treat cancer…
July 23, 2024
The Democratization of Compute
A Paradigm Shift in Business and Investment Artificial Intelligence (AI) is undeniably transformative, poised to revolutionize the world as we...
![Kerry Grinkmeyer in a suit standing in front of a stock chart with a bull on it](https://bestofusinvestors.com/uploads/2023/07/kerry-300x300.webp)
Kerry Grinkmeyer
July 23, 2024
Are Google and Meta Heading for a Stock Price Slump?
As an investor, it's crucial to keep a keen eye on market trends and potential shifts that could impact major players. Today, I want to discuss two tech giants that have long been darlings of Wall Street: Google and Meta. While they've enjoyed impressive growth and dominance in their respective fields, there are signs that their stock prices might face some headwinds in the near future.
As an investor, it's crucial to keep a keen eye on market trends and potential shifts that could impact major...
![Trent Grinkmeyer in front of stock market with bull background](https://bestofusinvestors.com/uploads/2023/06/trent-e1687263019450-300x300.webp)
Trent Grinkmeyer
July 23, 2024